Bio Path — Company Overview, News & Financial Data
Bio Path focuses on developing genetic cancer treatments utilizing its DNAbilize® platform to improve safety and efficacy for patients.
About Bio Path
Bio Path (NASDAQ:BPTH) is a biotech company focused on developing genetic cancer treatments using its proprietary drug delivery platform, DNAbilize®. This innovative technology aims to provide safer, more effective treatment options by specifically targeting cancer cells while sparing healthy ones, primarily focusing on blood cancers and solid tumors. Their portfolio includes promising preclinical and clinical-stage projects aiming to improve patient outcomes and address unmet medical needs in cancer therapy. The company's primary objective is to advance its lead drug candidate, Prexigebersen, through the necessary clinical trials to bring a new generation of cancer treatments to the market.
Snapshot
Operations
Products and/or services of Bio Path
- Prexigebersen, a novel therapy targeting acute myeloid leukemia.
- BP1002, targeting solid tumors including lymphomas.
- BP1003, designed to inhibit the STAT3 pathway in pancreatic cancer.
- Development of nucleic acid therapeutics using DNAbilize platform.
- Research collaboration on DNAbilize antisense RNA technology for cancer treatment.
- Partnership initiatives to expand the pipeline of cancer therapies.
Bio Path executive team
- Mr. Peter H. Nielsen MBACo-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
- Mr. Douglas P. MorrisCo-Founder, Director of Investor Relations, Secretary & Director
- Mr. Michael Hickey M.B.A.VP of Clinical Operations
- Mr. Anthony Price MBASenior Vice President of Finance, Accounting & Administration
- Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D.Senior Vice President of Research, Development & Clinical Design